X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (182) 182
index medicus (156) 156
gastroenterology & hepatology (117) 117
male (111) 111
female (110) 110
middle aged (89) 89
adult (79) 79
aged (73) 73
gastroenterology and hepatology (61) 61
abridged index medicus (36) 36
prospective studies (35) 35
treatment outcome (34) 34
cancer (27) 27
oncology (26) 26
retrospective studies (25) 25
colorectal cancer (24) 24
endoscopy (24) 24
aged, 80 and over (23) 23
colonoscopy (23) 23
risk factors (23) 23
surgery (23) 23
diagnosis (20) 20
pharmacology & pharmacy (19) 19
adolescent (17) 17
management (17) 17
risk (17) 17
therapy (17) 17
tumors (17) 17
analysis (16) 16
follow-up studies (16) 16
prevention (15) 15
time factors (15) 15
anti-inflammatory agents, non-steroidal - adverse effects (14) 14
care and treatment (14) 14
ulcerative colitis (14) 14
young adult (14) 14
animals (13) 13
colorectal neoplasms - pathology (13) 13
crohns-disease (13) 13
ulcerative-colitis (13) 13
france (12) 12
medicine & public health (12) 12
patients (12) 12
biopsy (11) 11
chemotherapy (11) 11
crohn's disease (11) 11
medicine, general & internal (11) 11
nonsteroidal antiinflammatory drugs (11) 11
adenoma - pathology (10) 10
antineoplastic combined chemotherapy protocols - therapeutic use (10) 10
bevacizumab (10) 10
colorectal neoplasms - prevention & control (10) 10
digestive system diseases (10) 10
gastroenterology (10) 10
inflammatory bowel disease (10) 10
chemoprevention (9) 9
cohort studies (9) 9
colorectal neoplasms - drug therapy (9) 9
colorectal-cancer (9) 9
dysplasia (9) 9
life sciences (9) 9
liver neoplasms - drug therapy (9) 9
medicine (9) 9
prognosis (9) 9
safety (9) 9
adenocarcinoma - pathology (8) 8
colon (8) 8
colonoscopy - methods (8) 8
colorectal carcinoma (8) 8
disease (8) 8
efficacy (8) 8
endoscopic submucosal dissection (8) 8
follow-up (8) 8
guidelines (8) 8
inflammatory bowel diseases (8) 8
lesions (8) 8
multivariate analysis (8) 8
organoplatinum compounds - administration & dosage (8) 8
research (8) 8
risk-factors (8) 8
surveillance (8) 8
adenocarcinoma (7) 7
adenoma - prevention & control (7) 7
aspirin (7) 7
cholangiopancreatography, endoscopic retrograde (7) 7
cyclooxygenase inhibitors - therapeutic use (7) 7
feasibility studies (7) 7
fluorouracil - administration & dosage (7) 7
health aspects (7) 7
inflammatory bowel diseases - drug therapy (7) 7
inflammatory-bowel-disease (7) 7
manometry (7) 7
medical research (7) 7
medicine, experimental (7) 7
original (7) 7
prevalence (7) 7
risk assessment (7) 7
science (7) 7
age factors (6) 6
antineoplastic agents - therapeutic use (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS ONE, ISSN 1932-6203, 05/2012, Volume 7, Issue 5, pp. e37563 - e37563
Background: Sorafenib induces frequent dose limiting toxicities (DLT) in patients with advanced hepatocellular carcinoma (HCC). Sarcopenia has been associated... 
TOMOGRAPHY | SKELETAL-MUSCLE | CANCER-PATIENTS | SOLID TUMORS | MULTIDISCIPLINARY SCIENCES | VALIDATION | BODY-COMPOSITION | INHIBITOR | PHASE-I | CARE | Niacinamide - analogs & derivatives | Humans | Middle Aged | Liver Neoplasms - drug therapy | Pyridines - pharmacokinetics | Antineoplastic Agents - therapeutic use | Benzenesulfonates - therapeutic use | Phenylurea Compounds | Benzenesulfonates - adverse effects | Dose-Response Relationship, Drug | Sarcopenia - chemically induced | Benzenesulfonates - pharmacokinetics | Pyridines - adverse effects | Carcinoma, Hepatocellular - drug therapy | Antineoplastic Agents - adverse effects | Liver Neoplasms - metabolism | Survival Analysis | Adult | Aged | Antineoplastic Agents - pharmacokinetics | Retrospective Studies | Carcinoma, Hepatocellular - metabolism | Pyridines - therapeutic use | Antimitotic agents | Medical research | Sarcopenia | Analysis | Diarrhea | Medicine, Experimental | Hepatoma | Antineoplastic agents | Liver cirrhosis | Nuclear magnetic resonance--NMR | Laboratories | Toxicity | Oncology | Hepatocellular carcinoma | Males | Body composition | Body mass index | Liver cancer | Angiogenesis | Toxicology | Computed tomography | Tomography | Nosocomial infections | Drug dosages | Teaching hospitals | Hypertension | Medical imaging | Pharmacology | Metabolism | Patients | Constraining | Feet | Musculoskeletal system | Clinical medicine | Pharmacokinetics | Cancer | Tumors | Index Medicus | Nuclear magnetic resonance | NMR | Computer aided tomography
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2011, Volume 364, Issue 19, pp. 1807 - 1816
Journal Article
PLoS ONE, ISSN 1932-6203, 2011, Volume 6, Issue 2, pp. e16978 - e16978
Portal hypertension, the most important complication with cirrhosis of the liver, is a serious disease. Sorafenib, a tyrosine kinase inhibitor is validated in... 
ADVANCED HEPATOCELLULAR-CARCINOMA | AZYGOS BLOOD-FLOW | BIOLOGY | TUMOR | PHASE-II | INVIVO VALIDATION | GROWTH-FACTOR | HYPERDYNAMIC SPLANCHNIC CIRCULATION | HYPERTENSIVE-RATS | RAF/MEK/ERK PATHWAY | VARICEAL HEMORRHAGE | Niacinamide - analogs & derivatives | Carcinoma, Hepatocellular - mortality | Hypertension, Portal - physiopathology | Humans | Middle Aged | Liver Neoplasms - complications | Male | Antineoplastic Agents - therapeutic use | Benzenesulfonates - therapeutic use | Phenylurea Compounds | Protein Kinase Inhibitors - adverse effects | Liver Neoplasms - mortality | Benzenesulfonates - adverse effects | Pyridines - adverse effects | Carcinoma, Hepatocellular - drug therapy | Hypertension, Portal - etiology | Regional Blood Flow - drug effects | Carcinoma, Hepatocellular - complications | Antineoplastic Agents - adverse effects | Adult | Female | Liver Neoplasms - pathology | Pyridines - therapeutic use | Liver Cirrhosis - drug therapy | Portal Vein - drug effects | Liver Cirrhosis - complications | Liver Neoplasms - drug therapy | Magnetic Resonance Angiography | Disease Progression | Hypertension, Portal - drug therapy | Portal Vein - physiology | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Hepatocellular - pathology | Survival Analysis | Aged | Liver Cirrhosis - physiopathology | Hypertension | Antimitotic agents | Tyrosine | Complications and side effects | Liver | Antineoplastic agents | Liver cirrhosis | Therapy | Oxidative stress | Nuclear magnetic resonance--NMR | Clinical trials | Oncology | Hepatocellular carcinoma | Collateral | Metastasis | Hemorrhage | Beta blockers | Liver cancer | Angiogenesis | Rodents | Aorta | Vascular endothelial growth factor | Drug dosages | Protein-tyrosine kinase | Liver diseases | Magnetic resonance | Patients | Flow | Esophagus | Cirrhosis | Alteration of flow | Index Medicus | Nuclear magnetic resonance | NMR
Journal Article
Journal Article
Hepato-Gastro and Oncologie Digestive, ISSN 2115-3310, 09/2016, Volume 23, Issue 7, pp. 574 - 576
Journal Article
Investigational New Drugs, ISSN 0167-6997, 10/2011, Volume 29, Issue 5, pp. 1090 - 1093
Journal Article
Journal Article
Gastroenterology, ISSN 0016-5085, 05/2019, Volume 156, Issue 6, pp. S-631 - S-631
Journal Article
Scientific Reports, ISSN 2045-2322, 12/2018, Volume 8, Issue 1, pp. 4162 - 4
In France, colorectal cancer (CRC) benefits from a nationwide screening program. The faecal immunochemical test (FIT) is being used since April 2015. The test... 
OCCULT BLOOD-TESTS | POPULATION | QUALITY-ASSURANCE | EUROPEAN GUIDELINES | MULTIDISCIPLINARY SCIENCES | Colon | Medical screening | Colorectal carcinoma | Colonoscopy | Colorectal cancer | Computer programs
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 10/2012, Volume 11, Issue 10, pp. 2284 - 2293
Journal Article
Investigational New Drugs, ISSN 0167-6997, 2/2012, Volume 30, Issue 1, pp. 376 - 381
Purpose The only drug that improves survival in hepatocellular carcinoma is sorafenib. FOLFOX-4 regimen is safe and widely used in patients with colorectal... 
5-fluorouracil | Chemotherapy | Oxaliplatin | Medicine & Public Health | Cirrhotic patients | Oncology | Hepatocellular carcinoma | Pharmacology/Toxicology | Liver transplantation | COLON-CANCER | ONCOLOGY | PHASE-II | PHARMACOLOGY & PHARMACY | SORAFENIB | GEMCITABINE PLUS OXALIPLATIN | Leucovorin - administration & dosage | Carcinoma, Hepatocellular - mortality | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Liver Transplantation - adverse effects | Humans | Middle Aged | Liver Cirrhosis - mortality | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Liver Neoplasms - mortality | Feasibility Studies | Liver Neoplasms - etiology | Organoplatinum Compounds - administration & dosage | Carcinoma, Hepatocellular - drug therapy | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Time Factors | Female | Liver Neoplasms - pathology | Carcinoma, Hepatocellular - etiology | Retrospective Studies | Chemotherapy, Adjuvant | Drug Administration Schedule | Liver Cirrhosis - complications | Liver Neoplasms - drug therapy | Carcinoma, Hepatocellular - surgery | Liver Neoplasms - surgery | Liver Transplantation - mortality | Treatment Outcome | Disease-Free Survival | Carcinoma, Hepatocellular - pathology | Survival Analysis | Aged | Organoplatinum Compounds - adverse effects | Paris | Complications and side effects | Care and treatment | Patient outcomes | Liver | Dosage and administration | Leucovorin | Transplantation | Hepatoma | Health aspects | Fluorouracil | Studies | Liver cancer | Pharmacology | Transplants & implants | Liver cirrhosis | Index Medicus
Journal Article
La Presse Medicale, ISSN 0755-4982, 2011, Volume 40, Issue 5, pp. 494 - 495
Journal Article
Gut, ISSN 0017-5749, 03/2019, Volume 68, Issue 3, pp. 577 - 578
In our experience of 349 ESDs for rectal lesions, recurrences occur in only 1.5% of cases for a mean size of 56.4 mm.9 Moreover, to the best of our knowledge,... 
colorectal adenomas | endoscopic polypectomy | GASTROENTEROLOGY & HEPATOLOGY | EMR | Colonoscopy | Mucosa | Rectum | Endoscopy | Cost analysis | Patients | Dissection | Cancer | Tumors
Journal Article
Gastrointestinal Endoscopy, ISSN 0016-5107, 2010, Volume 72, Issue 4, pp. 728 - 735
Journal Article
Journal Article